GALT vs. RIGL, TRVI, OMER, GBIO, OVID, LFCR, ATOS, RENB, ACRV, and MACK
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Rigel Pharmaceuticals (RIGL), Trevi Therapeutics (TRVI), Omeros (OMER), Generation Bio (GBIO), Ovid Therapeutics (OVID), Lifecore Biomedical (LFCR), Atossa Therapeutics (ATOS), Renovaro (RENB), Acrivon Therapeutics (ACRV), and Merrimack Pharmaceuticals (MACK). These companies are all part of the "medical" sector.
Galectin Therapeutics (NASDAQ:GALT) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
Rigel Pharmaceuticals has higher revenue and earnings than Galectin Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 6 mentions for Galectin Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.51 beat Galectin Therapeutics' score of -0.80 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
Galectin Therapeutics has a net margin of 0.00% compared to Rigel Pharmaceuticals' net margin of -16.45%.
Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 240.56%. Rigel Pharmaceuticals has a consensus price target of $5.81, suggesting a potential upside of 511.58%. Given Rigel Pharmaceuticals' higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Galectin Therapeutics.
Rigel Pharmaceuticals received 106 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 60.21% of users gave Galectin Therapeutics an outperform vote.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Galectin Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats Galectin Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
